
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+7
Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology, ELUTYXTM. Ocular Therapeutix has built a robust product pipeline of drug delivery solutions developed to reduce the complexity and burden of the current standard of care and position itself to become a leader in the ophthalmic space. Ocular Therapeutix has a commercially available drug product, DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use. DEXTENZA is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following...
Ocular drug delivery,surgical sealants,sustained delivery,ophthalmic therapies,ophthalmology,optometry,retina,cataract,glaucoma,wet amd,anti-vegf,and drug delivery
Ocular therapeutix, inc operates in the Pharmaceutical manufacturing industry.
Ocular therapeutix, inc's revenue is 11m - 100m
Ocular therapeutix, inc has 201 - 500 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.